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oThe immediate vascular injury following balloon
angioplasty and stent implantation initiates vascular
smooth muscle cell proliferation and neointima
formation that may lead to in-stent restenosis
(ISR), the principal cause for percutaneous inter-
vention (PCI) failure. Drug-eluting stents (DES)
have greatly reduced the problem of ISR by target-
ing proliferating cells, but the beneficial reductions
in neointima formation and ISR are accompanied
by impaired endothelial regeneration and vascular
healing that has created a host of new concerns (1).
See page 71
The foremost is the issue of delayed re-endo-
thelialization and its association with increased risk
for stent thrombosis especially late after 1 year.
Multiple studies have documented the increased
incidence of late stent thrombosis in DES com-
pared with BMS (2,3). This has led to recommen-
dations for prolonged dual antiplatelet therapy
(DAPT) with aspirin and clopidogrel for at least 1
year in patients with DES (4). Many other issues
less obvious on angiography than a stent thrombosis
have emerged from the woodwork as consequences
of DES. Localized hypersensitivity reactions to the
polymer have been associated with peri-strut cavity
and aneurysm formation (5). In addition, recent
pathological studies have identified the phenome-
non of “neoatherosclerosis” in stented vessels (6),
wherein impaired endothelial regeneration facili-
tates lipid deposition within the neointima poten-
tially increasing risk of plaque rupture and late
events (7). In this issue of iJACC, Nakano et al. (8)
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contents of this paper to disclose.ring these to light by examining the capability of
ptical frequency domain imaging (OFDI), aka
econd-generation optical coherence tomography
OCT), to characterize the various morphological
nd histological responses of human coronary stent
mplants in comparison to intravascular ultrasound
IVUS).
This postmortem study examined 14 human
tented coronary segments explanted 1 month
rom implantation by OFDI and IVUS and com-
ared them with histology for accuracy of morpho-
ogical measurements, detection of uncovered
truts, and characterization of neointima. The study
omprises a number of key observations. First, the
rea measurements (stent, lumen, neointima) and
ercent stenosis derived from IVUS, OFDI, and
istology are similar. From a clinical standpoint
hese measurements, particularly percent stenosis,
re important as they guide interventional therapy.
he value of this assessment cannot be underesti-
ated as it provides the first comparison of current
eneration IVUS and OCT to histology. That
eing said, the true novelty of this report examines
he utility of OFDI and IVUS in examining neo-
ntimal coverage and the ratio of uncovered stent
truts per section (RUTSS), the parameter reported
o offer the best morphometric correlate of the
xtent of endothelialization and risk of stent throm-
osis (1). The investigators report that OFDI was
uperior in examining neointimal coverage and the
UTSS compared with IVUS and further that
FDI was able to detect individual uncovered stent
truts with high sensitivity and specificity (9).
An imaging modality able to reliably detect
UTSS could help predict patients at high risk of
tent thrombosis from those who could safely dis-
ontinue DAPT. Since the recent revelation from
he DESERT (Drug Eluting Stent Event Registry
f Thrombosis) registry reporting that approxi-
ately 75% of stent thromboses occurred after 1
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84year following DES implantation, there has
emerged a pressing need to develop strategy to
identify patients at the highest risk of late stent
hrombosis. In the DESERT registry of 478 stent
hromboses, nearly 30% of patients who had events
ere taking DAPT at the time of the event, whereas
f those not taking DAPT, 44% of patients had
topped the drugs within 5 days. Such findings raise
any unanswered questions. Is re-endothelialization
Coronary Angiography, OCT, and NIRS in Very Late Stent
is
ary angiogram showing a 99% in-stent restenosis with hazy
e in the mid left anterior descending coronary artery at the
aclitaxel-eluting stent placed 50 months prior after cessation
therapy for asymptomatic hematuria. (B to F) Optical coher-
graphy (OCT) identiﬁed a number of risk factors for stent
s in this patient, not possible with coronary angiography alone.
owing peri-strut cavity formation (asterisk) exposed uncov-
struts (white arrowheads) and white thrombus (grey arrow-
) Exposed stent struts 5 mm distal to the previous image con-
how exposed uncovered stent struts (white arrowheads) and
e white thrombus (grey arrowheads). (E) Further progression
hrombus 5 mm from the previous image (grey arrowheads)
red struts. (F) Point of maximal thrombus was at the site of
lap with underexpansion (black arrowheads) also showing mi-
ls (white arrows) consistent with recanalization. Scale bar  1
 near-infrared spectroscopy.ith DES delayed or does it remain persistentlyincomplete? Is there an association between the find-
ing that 30% of patients had stent thromboses while
taking DAPT, and nearly the same percentage are
clopidogrel nonresponders? What is the optimal du-
ration of DAPT? Could OCT help answer at least
some of these concerns? And, if so, what would be the
best clinical counterpart of pathologically verified
RUTSS?
Because outcome data for the utility of uncovered
stent struts as a surrogate for re-endothelialization,
and thus risk of stent thrombosis, is lacking, we
have recently initiated a randomized study investi-
gating the utility of OCT-defined ratio of uncov-
ered struts to determine which patients with DES
who need to stop DAPT (e.g., need for urgent
surgery, active bleeding) may safely do so. In addi-
tion, we make an effort to evaluate all patients who
have received stents in the past and are being
recatheterized for culprit or nonculprit lesions by
OCT. Among these were patients who stopped
DAPT for elective colonoscopy (23 months), new
onset atrial fibrillation with initiation of dabigatran
(27 months), and new onset hematuria (50
months). Using OCT, we found risk factors for
stent thrombosis not detectable angiographically,
such as uncovered stent struts (1,7), peri-stent
cavity formation (5), and stent underexpansion
(10–13) (Fig. 1).
There is no prospective outcome data to con-
firm the validity of RUTSS in vivo. Strut cover-
age is used as a surrogate for neointimal coverage,
which is used as a surrogate for re-endothelialization,
which is used as a surrogate for vascular healing, which
is used as a surrogate for risk of stent thrombosis. This
serial surrogacy is somewhat like playing musical
chairs; somewhere there is risk of the message being
distorted or lost. In fact, in our experimental work
neointimal coverage has no direct correlation with
re-endothelialization in conditions of disease (Fig. 2).
It is unknown whether exposed stent strut is more
or less thrombogenic than neointima without en-
dothelium. In the absence of an endothelial mono-
layer, primary hemostasis is activated by exposure of
subendothelial components such as collagen and
von Willebrand factor to platelets and coagulation
by exposure of tissue factor to blood containing
coagulation factors (14). Histological analysis in the
paper by Nakano et al. (8) reported the presence of
fibrin overlying stent struts. Perhaps the fibrin
serves as a more potent nidus than exposed neoin-
tima. The authors pointed out that in their analysis
of OFDI versus histology there were a few falseFigure 1.
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85deemed to be covered by neointima but were
actually covered by fibrin. However, they found that
using OFDI signal intensity ratio, an optical density
measurement, they were able to reliably differentiate
between fibrin and normal neointima in humans as
others have shown in animal models (15). Micro-
OCT has recently been described, which has image
resolution an order of magnitude better than
second-generation OCT and is able to image sub-
cellular structures (16). It remains to be seen
whether such a technology would obviate the need
for use of neointimal coverage and RUTSS as a
surrogate for re-endothelialization (1). Until then,
in the setting of observational data showing that
DAPT discontinuation at 6 months does not in-
crease risk of stent thrombosis in patients implanted
with zotarolimus-eluting stents (ZES) (17) coupled
with OCT data showing almost complete neointi-
mal coverage at 9 months with ZES (18), OFDI
assessment of stent coverage certainly warrants
assessment as a tool to identify patients at risk of
stent thrombosis.
The expectation for application of new tech-
nologies in this era of healthcare economics and
comparative effectiveness is to show an improved
outcome outweighing additional cost. Previous
studies have shown a cost benefit for IVUS-
guided PCI (19), and data from the MATRIX
registry reported a reduction in death, myocardial
infarction, and target vessel revascularization
(20). Such data are lacking for OCT, but inves-
Figure 2. Neointimal Strut Coverage and Re-Endothelialization
(A) Cross section of stented vessel from a hypercholesterolemic
Tie2-LacZ reporter gene showing complete stent strut coverage
cells depicted by short black arrowheads are endothelial cells. S
no endothelium. (B) En face imaging shows the same ﬁnding lon
black arrowheads) are endothelial cells. Large gaps in endotheli
mal coverage. The long arrowhead shows a stent strut that was
longitudinally.indirect evidence for OCT being able to provide
at least the same benefits. Multicenter OCT
registries have only recently begun and should
prove to be useful data sources for outcomes
analyses. In the meantime OCT is being more
commonly used in clinical trials for assessment of
stent characteristics, specifically stent apposition
and neointimal coverage. As the next generation
of stents include bioabsorbable vascular scaffolds
that will require detailed analyses of strut integ-
rity for both safety and efficacy (21), OCT will
play an integral part of vascular scaffold follow-
up. For now, we use OCT as our modality of
choice for stent evaluation at the time of the
index procedure with particular reference to stent
apposition, stent expansion, and identification of
vessel injury such as edge dissection. In ensuing
times, we will employ OCT for stent apposition
and strut coverage in follow-up after DES place-
ment and assessment of restenosis and thrombus.
By correlating OFDI imaging with histology,
Nakano et al. (8) have strengthened the useful-
ness of OCT as a reliable method for assessing
RUTSS in vivo, giving interventionalists the
chance to finding the uncovered tracks left be-
hind.
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rosclerotic apolipoprotein-E knockout mouse with endothelial
g black arrowhead) but only partial re-endothelialization. Blue
t white arrowheads show area of neointimal hyperplasia with
dinally. Blue cells on the surface of the stented vessel (short
tion (white arrowheads) are present despite complete neointi-
bedded in neointima (asterisk) prior to being cuttigations such as the one presented here offer samin.sharma@mountsinai.org.athe
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